Cerevel Granted Fast Track Designation By The U.S. FDA For CVL-871 For Apathy - Quick Facts

India, June 15 -- Cerevel Therapeutics (CERE) announced Tuesday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CVL-871, a D1/D5 partial agonist in development for the treatment of dementia-related apathy.

Apathy is a strong predictor of dementia progression and can lead to decreased quality of life, increased morbidity and mortality, early institutionalization, and significant caregiver burden.

For comments and feedback contact: [e-mail]

Published by HT Digital Content Services with permission from RTT News....